BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zarepour L, Gharaylou Z, Hadjighassem M, Shafaghi L, Majedi H, Behzad E, Hosseindoost S, Ramezani F, Nasirinezhad F. Preliminary study of analgesic effect of bumetanide on neuropathic pain in patients with spinal cord injury. J Clin Neurosci 2020;81:477-84. [PMID: 33222966 DOI: 10.1016/j.jocn.2020.10.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Pressey JC, de Saint-Rome M, Raveendran VA, Woodin MA. Chloride transporters controlling neuronal excitability. Physiol Rev 2023;103:1095-135. [PMID: 36302178 DOI: 10.1152/physrev.00025.2021] [Reference Citation Analysis]
2 Gharaylou Z, Shafaghi L, Pestehei SK, Hadjighassem M. Long-term bumetanide administration altered behavioral pattern in mosaic Down's Syndrome: A case report. Appl Neuropsychol Child 2023;12:88-95. [PMID: 34860628 DOI: 10.1080/21622965.2021.2007481] [Reference Citation Analysis]
3 Pushparaj PN, Kalamegam G, Ramakrishna S. Editorial: Methods and application in integrative and regenerative pharmacology: 2021. Front Pharmacol 2022;13:1077352. [PMID: 36506581 DOI: 10.3389/fphar.2022.1077352] [Reference Citation Analysis]
4 Hashemizadeh S, Gharaylou Z, Hosseindoost S, Sardari M, Omidi A, Hosseini ravandi H, Hadjighassem M. Long-term administration of bumetanide improve functional recovery after spinal cord injury in rats. Front Pharmacol 2022;13:932487. [DOI: 10.3389/fphar.2022.932487] [Reference Citation Analysis]
5 Hange N, Poudel S, Ozair S, Paul T, Nambakkam M, Shrestha R, Greye F, Shah S, Raj Adhikari Y, Thapa S, Patel P, De Carvalho M. Managing Chronic Neuropathic Pain: Recent Advances and New Challenges. Neurology Research International 2022;2022:1-14. [DOI: 10.1155/2022/8336561] [Reference Citation Analysis]
6 Hudson KE, Grau JW. Ionic Plasticity: Common Mechanistic Underpinnings of Pathology in Spinal Cord Injury and the Brain. Cells 2022;11:2910. [PMID: 36139484 DOI: 10.3390/cells11182910] [Reference Citation Analysis]
7 Savardi A, Borgogno M, De Vivo M, Cancedda L. Pharmacological tools to target NKCC1 in brain disorders. Trends Pharmacol Sci 2021;42:1009-34. [PMID: 34620512 DOI: 10.1016/j.tips.2021.09.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
8 Borgogno M, Savardi A, Manigrasso J, Turci A, Portioli C, Ottonello G, Bertozzi SM, Armirotti A, Contestabile A, Cancedda L, De Vivo M. Design, Synthesis, In Vitro and In Vivo Characterization of Selective NKCC1 Inhibitors for the Treatment of Core Symptoms in Down Syndrome. J Med Chem 2021;64:10203-29. [PMID: 34137257 DOI: 10.1021/acs.jmedchem.1c00603] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
9 Mazzone GL, Mohammadshirazi A, Aquino JB, Nistri A, Taccola G. GABAergic Mechanisms Can Redress the Tilted Balance between Excitation and Inhibition in Damaged Spinal Networks. Mol Neurobiol 2021;58:3769-86. [PMID: 33826070 DOI: 10.1007/s12035-021-02370-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]